amgen

Abbott, Amgen Are On the Prowl with Small Deals

Pfizer Pushes into Biotech Generics

Pfizer may be hatching plans to sell "biosimilars," cheaper versions of biotech medicines, of drugs developed by the world's largest independent biotech Amgen. That's causing concern not just at Amgen, but at other biotechs that fear such competition.

Amgen's stock buyback plan could boost shares

Amgen's troubles keep compounding; Aranesp studies reveal greater risks

Amgen's bone drug gets delayed by the FDA, and Wall Street isn't surprised

New drug helps prevent osteoporosis, but the downside could be cancer

Amgen jumps 15 percent on results of clinical trial